NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Aytu BioPharma, Inc. (AYTU) Stock Analysis

Aytu BioPharma, Inc. (AYTU) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AYTU

$1.96

−$0.05 (−2.49%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AYTU with… →

AYTU Key Statistics

As of Oct 21, 2026
Trading
Open
$1.99
Previous Close
$2.01
Day's Range
1.96–2.12
52-Week Range
1.80–3.07
Volume
6.83K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.18
Valuation
Market Cap
$21.84M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
12.97
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.38
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.16
Financials (FY)
Revenue (FY)
$66.38M+1.84%
Net Income (FY)
−$13.56M
Profit marginThe share of revenue left as profit after all costs and taxes.
−24.76%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
10.87M
1-Year Return
−16.95%
Dividend and dates
Avg Volume
34.84K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AYTU closed at $1.96, −16.95% over 1 year.

Aytu BioPharma, Inc. (AYTU) has a market capitalization of $21.84M.

In fiscal 2025, AYTU reported revenue of $66.38M.

AYTU Stock Return by Calendar Year

Aytu BioPharma, Inc. (AYTU) 10-year return: what $10,000 became

1 year
$10,000 $8,305
−16.95%
5 years
$10,000 $383
−96.17%
10 years
$10,000 $0.11
−99.999%

If you had invested $10,000 in Aytu BioPharma, Inc. (AYTU) 10 years ago, at the close on October 21, 2016, it would have been worth $0.11 at the close on October 21, 2026: −99.999% in total, −68.04% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.62%
2025+52.94%
2024−40.14%
2023−25.26%
2022−85.93%
2021−77.42%
2020−38.35%
2019+22.78%
2018−98.23%
2017−90.71%
2016 (partial year)−66.67%

As of October 21, 2026.

AYTU Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$66.38M−$13.56M−20.4%
2024$65.18M−$15.84M−24.3%
2023$107.40M−$17.05M−15.9%
2022$96.67M−$108.78M−112.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$66.38M$45.83M$2.54M−$13.56M−20.4%
2024$65.18M$49.05M$565.00K−$15.84M−24.3%
2023$107.40M$66.63M−$12.33M−$17.05M−15.9%
2022$96.67M$52.28M−$36.10M−$108.78M−112.5%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

AYTU Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricAYTUDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.382.100.2x the median
Profit margin−24.76%−8.14%16.6 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Aytu BioPharma, Inc. (AYTU) is capitalised at $21.84M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 75 employees.

Over the past 52 weeks the price has ranged from $1.80 to $3.07. The most recent close on file for AYTU is $1.96, dated October 21, 2026. That is −$0.05 (−2.49%) against the previous close. The latest close sits 8.89% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $66.38M. Against the prior fiscal year total of $65.18M, that is a change of +1.84%. The same year closed with a net loss of $13.56M. Profit margin runs at −24.76%. That is 16.6 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −1.16.

Across the 4 fiscal years on file, revenue moves from $96.67M in 2022 to $66.38M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 12.97. Measured against sales, the shares trade at 0.38 times revenue. On price-to-sales that is 0.2 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year total return is −16.95%. Measured over 10 years, that is −68.04% a year compounded. Beta against the wider market is reported at 0.18. Daily returns over the trailing 10 years annualize to a volatility of 182.68%.

Growth & Income

The record shows no dividend for AYTU.

2026 is still running; the total return is −24.62% year to date. Across the complete calendar years on file, 2025 returned +52.94% and 2018 returned −98.23%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Aytu BioPharma, Inc. (AYTU) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aytu BioPharma, Inc. AYTU $21.84M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Aytu BioPharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Aytu BioPharma, Inc.

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Visit website →